Agran Libbie’s Catalyst Pharmaceutical CPRX Stock Holding History

Agran Libbie’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$86K	Hold	44,000	–	–	0.02%	121
2016 Q4	$46K	Hold	44,000	–	–	0.01%	120
2016 Q3	$48K	Hold	44,000	–	–	0.01%	107
2016 Q2	$31K	Sell	44,000 -200	-0.5%	-$161	0.01%	124
2016 Q1	$56K	Buy	44,200 +10,000	+29%	+$15.5K	0.01%	119
2015 Q4	$87K	Hold	34,200	–	–	0.02%	120
2015 Q3	$106K	Buy	34,200 +200	+0.6%	+$863	0.03%	118
2015 Q2	$140K	Hold	34,000	–	–	0.04%	118
2015 Q1	$147K	Buy	34,000 +14,000	+70%	+$50.5K	0.04%	135
2014 Q4	$59K	Hold	20,000	–	–	0.01%	128
2014 Q3	$66K	Buy	+20,000	New	+$52.3K	0.02%	124

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Agran Libbie's CPRX Position: Q1 2017 in Review

Agran Libbie held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2017 at 44,000 shares worth $86K. The position accounts for 0.02% of the portfolio, ranked #121.

Agran Libbie first reported a position in CPRX in Q3 2014 and has held it in 11 quarters since. The position peaked at $147K in Q1 2015. 50 funds tracked by Wall St. Rank hold CPRX as of Q1 2017.

Agran Libbie held 44,000 shares of Catalyst Pharmaceutical worth $86K as of Q1 2017.
Agran Libbie left its Catalyst Pharmaceutical share count unchanged in Q1 2017.
Catalyst Pharmaceutical made up 0.02% of Agran Libbie's portfolio in Q1 2017, its #121 holding.
Agran Libbie first reported a position in Catalyst Pharmaceutical in Q3 2014 and has held it in 11 quarters since.
Agran Libbie's Catalyst Pharmaceutical position peaked at $147K in Q1 2015.
50 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2017.

Based on Agran Libbie's 13F filing for Q1 2017, filed 27 Apr 2017.